Acromegaly is a rare and serious condition related to the
hypersecretion of growth hormone by the pituitary gland,
generally of tumoral origin. This causes an uncontrolled growth
of organs, debilitating symptoms and a shorter life expectancy.
Pharmacotherapy with somatostatin analogs is one of the treatment options, a life-long treatment with a few and mild side effects. Novartis’ Sandostatin® (octreotide) is the market leader and which efficacy is clearly established for treating acromegaly. The yearly treatment with the long-acting release (LAR) formulation of the product, which consists of intramuscular injections every 4 weeks, is costly. Difficult reconstitution prior to injection is also an issue.
Ambrilia has developed an improved, proprietary prolonged release formulation of Octreotide (C2L) for which Phase III results have indicated its ability to replace Sandostatin LAR® with less frequent injections and non inferior efficacy, and comparable safety. C2L is easier to reconstitute and could be the first therapeutic alternative to Sandostatin®LAR.
Ambrilia’s C2L is available for licensing. For more information, please contact:
Daniel Böck, Ph.D.
Vice-President, Business Development and Licensing
Tel.: 514 751-2003 ext. 236
E-mail: dbock@ambrilia.com
Sandostatin®LAR is a registered trademark of Novartis Pharmaceuticals
Improved formulation of Sandostatin®LAR
Acromegaly and rare digestive tumors
Phase III
Patented delivery system technology
TEVA: France, Germany, Benelux, Spain, Scandinavia
Archimedes Pharma: U.K.
Gerolymatos: Greece, Turkey and other countries
Kwidza Pharma: Austria
Omega: Canada, Egypt
Pharmis: Portugal, Brazil
Shin Poong: Korea